**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Scientific Exchange | **Project Code** | PB4LOT098 |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** | Chelsey Goins |
| **Compliance** | ---------- | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests: N/A

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**~~Slides Synched? (if included in webcast)~~**

~~Yes~~

~~No~~

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
**CME?**

Yes

No

**~~CME Posttest Link:~~**

**Webcast/PDS URL: www.primeoncology.org/biosimilarslidekit**

**~~Additional Components~~**

~~Cases with Voting~~

~~Polls~~

~~Video Segmentation~~

~~Table of Contents~~

~~Other:~~

**~~Mobile App Title:~~**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[Meeting-Associated Downloadable Slides]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Biosimilars 101: A Comprehensive Guide for Breast Oncologists**

**ACTIVITY FEATURES**

[Icon] Downloadable Slides

**ACTIVITY OVERVIEW**

prIME Oncology invites you to view an educational slide deck on biosimilars that provides in-depth information for breast cancer specialists.

~~\*\*\*May add a “in conjunction with \_\_\_\_\_\_\_” phrase if this is from a symposium at a congress.~~

**PROVIDER**

This activity is provided by prIME Oncology.

**[Tab—Biosimilars]**

Featured Topics:

* What is a biosimilar?
* Why are biosimilars of monoclonal antibodies different from other biosimilars?
* How are biosimilars regulated in Europe?
* What biosimilars are currently approved in the EU?
* How do clinical trials for biosimilar monoclonal antibodies differ from other clinical trials?
* Are any biosimilars in development for breast cancer?
* What is extrapolation?
* What safety measures are in place after biosimilars are approved?

**SUPPORTER**

This educational activity is supported by F. Hoffmann-La Roche Ltd.

**ACTIVITY DATE**

Release Date

Expiration Date

**~~MOBILE APP VIEW ACTIVITY TEXT PER VIDEO~~**~~Insert presentation-specific text for the “View Activity” action item on the mobile app.~~

1. **~~[Meeting-Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included~~**